Skip to main content
    R

    Replimune Group Inc (REPL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $21.41
    -0.48 (-2.19%)

    Market Cap: $2.08B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Replimune Group Inc (REPL) Earnings: Report Dates and Results

    Updated Oct 28, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Replimune Group (REPL) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, Replimune Group reported EPS of -$0.54, above the -$0.70 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    35%(12/34)
    Avg Surprise
    -23.22%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.47
    Range-$0.49 - -$0.45
    4 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.56+15.6%
    60d ago-$0.79+40.5%
    30d ago-$0.76+38.1%
    7d ago-$0.76+38.1%
    Current-$0.47
    Revenue Consensus
    $7.19M
    RangeN/A
    7 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.61
    Range-$0.82 - -$0.43
    9 analysts
    Revenue Consensus
    $28.09M
    Range$1.96M - $66.15M
    8 analysts

    Next Report

    REPL has an expected report date of Feb 1, 2027.

    REPL Earnings Call

    The latest REPL earnings call transcript on file is labeled 2025Q4.

    Read the 2025Q4 transcript

    Earnings History

    Of the 34 quarters below that had an estimate, REPL beat 12, missed 19 and matched 3. The widest gap in the table came in the quarter ended Jun 30, 2018, when EPS landed 778.26% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$0.54-$0.70N/A+22.86%BeatN/A20 up, 0 downOct 28, 2026
    Jun 30, 2026-$0.72-$0.72N/A0.00%In lineN/A30 up, 1 downAug 14, 2026
    Mar 31, 2026-$0.76-$0.73N/A-4.11%MissN/A40 up, 0 downJun 29, 2026
    Dec 31, 2025-$0.77-$0.82-$0.93 - -$0.71+6.10%BeatN/A53 up, 1 downFeb 3, 2026
    Sep 30, 2025-$0.90-$0.79-$0.89 - -$0.70-13.92%MissN/A52 up, 1 downNov 6, 2025
    Jun 30, 2025-$0.95-$0.83-$0.90 - -$0.66-14.46%MissN/A60 up, 1 downAug 7, 2025
    Mar 31, 2025-$0.82-$0.69-$0.74 - -$0.64-18.84%MissN/A31 up, 1 downMay 22, 2025
    Dec 31, 2024-$0.79-$0.72-$0.73 - -$0.71-9.72%MissN/A20 up, 0 downFeb 12, 2025
    Sep 30, 2024-$0.68-$0.74-$0.83 - -$0.69+8.11%BeatN/A70 up, 0 downNov 12, 2024
    Jun 30, 2024-$0.78-$0.83-$1.10 - -$0.70+6.02%BeatN/A80 up, 0 downAug 8, 2024
    Mar 31, 2024-$0.25-$0.80-$0.86 - -$0.70+68.75%BeatN/A80 up, 0 downMay 16, 2024
    Dec 31, 2023-$0.77-$0.93-$1.01 - -$0.85+17.20%BeatN/A80 up, 0 downFeb 8, 2024
    Sep 30, 2023-$0.90-$0.89-$0.99 - -$0.80-1.12%MissN/A90 up, 0 downNov 7, 2023
    Jun 30, 2023-$0.75-$0.84-$0.93 - -$0.80+10.71%BeatN/A71 up, 0 downAug 3, 2023
    Mar 31, 2023-$0.74-$0.66-$0.78 - -$0.59-12.12%MissN/A82 up, 0 downMay 18, 2023
    Dec 31, 2022-$0.69-$0.74-$0.84 - -$0.63+6.76%BeatN/A90 up, 0 downFeb 9, 2023
    Sep 30, 2022-$0.79-$0.76-$0.85 - -$0.74-3.95%MissN/A90 up, 0 downNov 3, 2022
    Jun 30, 2022-$0.78-$0.56N/A-39.29%MissN/AN/A0 up, 0 downAug 4, 2022
    Mar 31, 2022-$0.60-$0.60-$0.65 - -$0.460.00%In lineN/A100 up, 0 downMay 19, 2022
    Dec 31, 2021-$0.57-$0.57-$0.63 - -$0.520.00%In lineN/A100 up, 0 downFeb 3, 2022
    Sep 30, 2021-$0.56-$0.52-$0.61 - -$0.50-7.69%MissN/A8N/ANov 4, 2021
    Jun 30, 2021-$0.53-$0.42-$0.52 - -$0.34-26.19%MissN/A8N/AAug 6, 2021
    Mar 31, 2021-$0.41-$0.38-$0.48 - -$0.34-7.89%MissN/A7N/AMay 20, 2021
    Dec 31, 2020-$0.42-$0.41-$0.47 - -$0.36-2.44%MissN/A8N/AFeb 4, 2021
    Sep 30, 2020-$0.46-$0.44-$0.49 - -$0.40-4.55%MissN/A8N/ANov 5, 2020
    Jun 30, 2020-$0.44-$0.43-$0.51 - -$0.41-2.33%MissN/A6N/AAug 7, 2020
    Mar 31, 2020-$0.41-$0.45-$0.49 - -$0.39+8.89%BeatN/A7N/AJun 3, 2020
    Dec 31, 2019-$0.46-$0.36-$0.43 - -$0.31-27.78%MissN/A5N/AFeb 13, 2020
    Sep 30, 2019-$0.35-$0.34-$0.41 - -$0.26-2.94%MissN/A7N/ANov 11, 2019
    Jun 30, 2019-$0.30-$0.31-$0.45 - -$0.25+3.23%BeatN/A6N/AAug 14, 2019
    Mar 31, 2019-$0.15-$0.40-$0.58 - -$0.33+62.50%BeatN/A4N/AJun 28, 2019
    Dec 31, 2018-$0.24-$0.25-$0.25 - -$0.23+4.00%BeatN/A3N/AFeb 14, 2019
    Sep 30, 2018-$0.26-$0.19N/A-36.84%MissN/AN/AN/ANov 14, 2018
    Jun 30, 2018-$2.02-$0.23-$0.24 - -$0.21-778.26%MissN/A3N/AJul 23, 2018
    Mar 31, 2018-$0.42N/AN/AN/AN/AN/AN/AN/AApr 11, 2018
    Last 35 quarters

    Annual EPS

    EPS for the fiscal year ended Mar 31, 2026 was -$3.38, after -$3.07 the year before. It was -$0.42 for the year ended Mar 31, 2018, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Mar 31, 2026-$3.38N/A
    Mar 31, 2025-$3.07N/A
    Mar 31, 2024-$2.67N/A
    Mar 31, 2023-$3.00N/A
    Mar 31, 2022-$2.26N/A
    Mar 31, 2021-$1.73N/A
    Mar 31, 2020-$1.52N/A
    Mar 31, 2019-$2.67N/A
    Mar 31, 2018-$0.42N/A

    Earnings Calls

    The only earnings call listed below, 2025Q4 for the period ended Dec 31, 2025, runs about 4,900 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q4Dec 31, 20254,88411

    2025Q4 Earnings Call

    Opening remarks

    Arleen Goldenberg Introduction Thank you, Operator, and good morning, everyone. Thank you for joining us today for a discussion of Replimune's fiscal year fourth quarter 2025 business highlights and financial results. Leading the call today will be Sushil Patel, our Chief Executive Officer. He will be joined by Chris Sarchi, our Chief Commercial Officer, and Emily Hill, our Chief Financial Officer. After our prepared remarks, we will open the call for Q&A. An audio recording and webcast replay for today's conference call will also be available online as detailed in the press release announcement for this call. During today's call, we will be making certain forward-looking statements, including, without limitations, statements about the potential safety, efficacy, and regulatory and clinical progress of our product candidates, our anticipated cash runway, and our future expectations, plans, partnerships, and prospects. These statements are subject to various risks such as changes in market conditions and difficulties associated with research and development and regulatory approval processes. These and other risk factors are described in the filings made with the SEC, including our annual report on Form 10-K and our Form 10-Q filed today. Forward-looking statements are based on the assumptions, opinions, and estimates of management at the date the statements are made, including the non-occurrence of the risk and uncertainties that are described in the filings made with the SEC or other significant events occurring outside of Replimune's normal course of business. You are cautioned not to place undue reliance on these forward-looking statements, which are made as of today, May 22, 2025. Replimune disclaims any obligation to update such statements, even if management's views change, except as required by law. With that, let me turn the call over to Sushil Patel, Replimune's Chief Executive Officer.

    Sushil Patel CEO Thank you, Arleen, and welcome everyone to today's earnings call. We appreciate you joining us as we review our fiscal fourth quarter and full year 2025 results. Today, we'll highlight the significant progress we've made across regulatory, clinical, and commercial as we approach the potential approval and launch of RP1. You'll also hear updates on our confirmatory Ignite 3 trial, pipeline developments for RP2, and our financial position as we prepare for commercial readiness. I'll begin with a strategic overview before turning the call over to Chris to walk through launch preparation and Emily to cover our financials. Replimune was founded to pioneer the next generation of oncolytic immunotherapy and is now poised to realize that promise with a substantial body of evidence supporting our mission. In particular, data from the Ignite Study shows that roughly one-third of patients are able to achieve a durable response in a high unmet need setting with few options.

    Frequently Asked Questions About REPL

    When is Replimune Group's next earnings date?

    Replimune Group's next earnings report is expected for Feb 1, 2027.

    Did REPL beat earnings estimates last quarter?

    Yes. Replimune Group reported EPS of -$0.54 for the quarter ended Sep 30, 2026, above the -$0.70 estimate, a 22.86% surprise.

    What EPS do analysts expect from REPL next quarter?

    The consensus EPS estimate for Replimune Group for the quarter ending Dec 31, 2026 is -$0.47 from 4 analysts, with estimates from -$0.49 to -$0.45.

    How often does REPL beat earnings estimates?

    Replimune Group beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -4.01%.